WaveRx goes under after FDA-weary investors pull the plug

August 19, 2011 by MassDevice staff

WaveRx Inc., a stealthy medical device company, shutters its doors after investors grow tired of waiting on FDA approval for its diabetic neuropathy treatment.


WaveRx Inc.'s head slipped under the water forever, a victim of its backers' doubts about the FDA ever giving a green light to its technology for treating diabetic neuropathy.

Mark Wan, a founding partner at Three Arch Partners, told the VentureWire blog that his VC company and its two other partners in WaveRx, 5AM Ventures and Polaris Venture Partners, shut the taps last year after waiting for an answer from the FDA's Center for Devices & Biological Health about its proposal for a re-vamped clinical trial.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.